StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)

Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%

Johnson & Johnson PROCRIT / EPREX [reported separately through FY2021Q4] by Year

PROCRIT / EPREX (epoetin alfa) [reported separately through FY2021Q4] — Worldwide sales ($M) ($M)

QuarterlyAnnual

Johnson & Johnson PROCRIT / EPREX [reported separately through FY2021Q4]: $479M in FY2021, down 13.2% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2021
479
Period ended Jan 2, 2022
Change on a year earlier
-13.2%
552 in FY2020
History
6 years
Since FY2016
Sources
3
Documents cited below

Where the FY2021 figure comes from

Source: Form 10-K (filed 2022-02-17) ↗

Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPROCRIT / EPREX (epoetin alfa) [reported separately through FY2021Q4] — Worldwide sales ($M) ($M)Year on yearSource
FY2021Jan 2, 2022479-13.2%Form 10-K (filed 2022-02-17) ↗
FY2020Jan 3, 2021552-30.1%Form 10-K (filed 2022-02-17) ↗
FY2019Dec 29, 2019790-20.0%Form 10-K (filed 2022-02-17) ↗
FY2018Dec 30, 2018988+1.6%Form 10-K (filed 2021-02-22) ↗
FY2017Dec 31, 2017972-12.0%Form 10-K (filed 2019-02-20) ↗
FY2016Jan 1, 20171,105–Form 10-K (filed 2019-02-20) ↗

Breakdown

What makes up PROCRIT / EPREX [reported separately through FY2021Q4]

Cite this data

StockData. (2026). Johnson & Johnson PROCRIT / EPREX [reported separately through FY2021Q4] ($M), annual FY2016–FY2021 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-procrit

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.